Novartis AG (NOVN)’s Tasigna and Glivec drugs won the backing of the U.K.’s health-cost agency for use against a rare blood cancer in final treatment guidelines.
The National Institute for Health and Clinical Excellence rejected a competing product, Bristol-Myers Squibb Co. (BMY)’s Sprycel, for use in patients with chronic myeloid leukemia, the agency said in a statement today. The agency advises the National Health Service on which medicines represent value for money.
Novartis offered a price cut that allowed a recommendation for Tasigna, and the Basel, Switzerland-based company asked that the discount be kept confidential, the agency said.
To contact the reporter on this story: Kristen Hallam in London at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com